Pharmaceutical - GlaxoSmithKline, Neurological

Filter

Popular Filters

1 to 25 of 29 results

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

GlaxoSmithKline divests rights to Treximet to Pernix for $250 million

15-05-2014

UK pharma giant GlaxoSmithKline will divest all of its rights to migraine drug Treximet (sumatriptan/naproxen…

GlaxoSmithKlineLicensingNeurologicalPernix TherapeuticsPharmaceuticalPozenTreximetUSA

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand

13-01-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to amend…

Asia-PacificBridionEli LillyFinancialGlaxoSmithKlineHealthcareLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalStrattera

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay

11-10-2013

The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

UK's OFT accuses GlaxoSmithKline of "market abuse"

19-04-2013

The UK's Office of Fair Trading (OFT) today (April 19) issued a Statement of Objections to certain pharmaceutical…

AlpharmaEuropeGenericsGlaxoSmithKlineLegalMarkets & MarketingNeurologicalNorton HealthcarePaxilPharmaceuticalPricingSeroxat

Patent briefs: Yaz patent invalid; FDA bars generic OxyContin; Appeals court backs GSK over Arzerra

17-04-2013

US generics major Actavis (NYSE: ACT, previously trading as Watson) said yesterday (April 16) that it…

ActavisArzerraBayerGenericsGenmabGlaxoSmithKlineNeurologicalNorth AmericaOncologyOxyContinPatentsPharmaceuticalPurdue PharmaReproductiveYaz

Anti-aging breakthrough could mean new drugs within five years

09-03-2013

Drugs that combat aging may be available within five years, following landmark work led by an Australian…

DiabetesGlaxoSmithKlineNeurologicalOncologyPharmaceuticalResearchresveratrol

Another stumbling block for Impax Pharma's Rytary

22-01-2013

Impax Pharmaceuticals, the branded products division of Impax Laboratories (Nasdaq: IPXL), revealed on…

GlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaPharmaceuticalProductionRegulationRytary

GSK and Canadian researchers claim major step toward an Alzheimer's vaccine

16-01-2013

A team of researchers from Canada's Universite Laval, CHU de Quebec, and UK pharma giant GlaxoSmithKline…

GlaxoSmithKlinemonophosphoryl lipid ANeurologicalPharmaceuticalResearchVaccines

Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide

15-01-2013

Confirming expectations announced when Pfizer (NYSE: PFE) revealed its $680 million acquisition of NextWave…

albiglutideDiabetesGlaxoSmithKlineMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalQuillivantRegulation

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK

20-12-2012

NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

Mayne Pharma to acquire Kapanol in Australia from GlaxoSmithKline for up to A$14.0 million

16-12-2012

Australia's Mayne Pharma Group (ASX: MYX) has entered into a binding agreement to acquire Kapanol and…

Asia-PacificGlaxoSmithKlineKapanolMayne PharmaMergers & AcquisitionsNeurologicalPharmaceutical

Research shows diabetes drug rosiglitazone improves memory

21-11-2012

Rosiglitazone, the active ingredient of GlaxoSmithKline's diabetes drug Avandia, has shown promise as…

AvandiaDiabetesGlaxoSmithKlineNeurologicalPharmaceuticalResearchrosiglitazone

GlaxoSmithKline gives up on XenoPort Horizant collaboration

09-11-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has reached an agreement with US partner XenoPort…

GlaxoSmithKlineHorizantLicensingNeurologicalPharmaceuticalXenoPort

EMA reviews hypothesis on Pandemrix hypothesis; finalizes on NSAIDs and CV events

21-10-2012

The European Medicines Agency's Committee on Human Medicinal Products (CHMP) said Friday that it has…

Anti-Arthritics/RheumaticsdiclofenacGlaxoSmithKlineibuprofenInflammatory diseasesNaproxenNeurologicalPandemrixPharmaceuticalRegulationVaccines

Leading dopamine agonists will continue to dominate Parkinson's market

19-08-2012

The leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol,…

Boehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingMirapexNeuproNeurologicalPharmaceuticalRequipRytaryUCB

Research news: dolutegravir; TD-1211; and synaptic modulators

11-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox

26-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

FDA clears GlaxoSmithKline's Horizant for PHN

08-06-2012

The US Food and Drug Administration (FDA) has approved UK Pharma giant GlaxoSmithKline's (LSE: GSK) Horizant…

GlaxoSmithKlineHorizantNeurologicalNorth AmericaPharmaceuticalRegulationXenoPort

1 to 25 of 29 results

Back to top